AP NEWS

Hospital Acquired Pneumonia (HAP) Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 6, 8, 11, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Hospital Acquired Pneumonia (HAP) - Overview Hospital Acquired Pneumonia (HAP) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development Aridis Pharmaceuticals Inc AstraZeneca Plc Cardeas Pharma Corp Centauri Therapeutics Ltd CytaCoat AB Destiny Pharma Ltd Dong-A Socio Holdings Co Ltd Evaxion Biotech ApS Lakewood-Amedex Inc MedImmune LLC Meiji Seika Pharma Co Ltd Melinta Therapeutics Inc Merck & Co Inc Motif Bio Plc Nabriva Therapeutics plc Polyphor AG Sealife PHARMA GMBH Shionogi & Co Ltd Tetraphase Pharmaceuticals Inc Theravance Biopharma Inc Wockhardt Ltd Zavante Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zgdzms/hospital_acquired?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006076/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS HOSPITALS INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 05:49 PM/DISC: 09/26/2018 05:49 PM

http://www.businesswire.com/news/home/20180926006076/en

AP RADIO
Update hourly